WO2006041641A3 - Therapeutic agents with decreased toxicity - Google Patents

Therapeutic agents with decreased toxicity Download PDF

Info

Publication number
WO2006041641A3
WO2006041641A3 PCT/US2005/033952 US2005033952W WO2006041641A3 WO 2006041641 A3 WO2006041641 A3 WO 2006041641A3 US 2005033952 W US2005033952 W US 2005033952W WO 2006041641 A3 WO2006041641 A3 WO 2006041641A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
decreased toxicity
toxicity
methods
relates
Prior art date
Application number
PCT/US2005/033952
Other languages
French (fr)
Other versions
WO2006041641A2 (en
Inventor
Mark S Dennis
Original Assignee
Genentech Inc
Mark S Dennis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Mark S Dennis filed Critical Genentech Inc
Priority to EP05810079A priority Critical patent/EP1796718A2/en
Priority to JP2007535700A priority patent/JP2008515889A/en
Priority to BRPI0516577-6A priority patent/BRPI0516577A/en
Priority to MX2007003907A priority patent/MX2007003907A/en
Priority to CA002583137A priority patent/CA2583137A1/en
Priority to AU2005294723A priority patent/AU2005294723A1/en
Publication of WO2006041641A2 publication Critical patent/WO2006041641A2/en
Publication of WO2006041641A3 publication Critical patent/WO2006041641A3/en
Priority to IL182261A priority patent/IL182261A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity agents and methods of treatment using the therapeutic agents with reduced toxicity.
PCT/US2005/033952 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity WO2006041641A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05810079A EP1796718A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
JP2007535700A JP2008515889A (en) 2004-10-05 2005-09-22 A therapeutic agent with reduced toxicity
BRPI0516577-6A BRPI0516577A (en) 2004-10-05 2005-09-22 therapeutic agents with reduced toxicity
MX2007003907A MX2007003907A (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity.
CA002583137A CA2583137A1 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
AU2005294723A AU2005294723A1 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
IL182261A IL182261A0 (en) 2004-10-05 2007-03-28 Therapeutic agents with decreased toxicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61650704P 2004-10-05 2004-10-05
US60/616,507 2004-10-05
US64153405P 2005-01-05 2005-01-05
US60/641,534 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006041641A2 WO2006041641A2 (en) 2006-04-20
WO2006041641A3 true WO2006041641A3 (en) 2006-06-29

Family

ID=36051453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033952 WO2006041641A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity

Country Status (11)

Country Link
US (2) US20060073152A1 (en)
EP (1) EP1796718A2 (en)
JP (1) JP2008515889A (en)
KR (1) KR20070073886A (en)
AU (1) AU2005294723A1 (en)
BR (1) BRPI0516577A (en)
CA (1) CA2583137A1 (en)
IL (1) IL182261A0 (en)
MX (1) MX2007003907A (en)
RU (1) RU2007116973A (en)
WO (1) WO2006041641A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE516818T1 (en) 2002-07-31 2011-08-15 Seattle Genetics Inc AURISTATIN CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
JP2008519863A (en) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Auristatin having an aminobenzoic acid unit at the N-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (en) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド Monomethylvaline compound having phenylalanine side chain modification at C-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (en) 2007-07-16 2014-07-02 健泰科生物技术公司 Humanized anti-CD79b antibodies and immunoconjugates and methods of use
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
MX2010008437A (en) 2008-01-31 2010-11-25 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use.
WO2009117531A1 (en) * 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
CN103620414A (en) 2011-06-28 2014-03-05 皇家飞利浦有限公司 Means used for examination of body fluids
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
WO2015030539A1 (en) 2013-08-30 2015-03-05 Aprilbio Co., Ltd An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
LT3262071T (en) 2014-09-23 2020-06-25 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
WO2019032827A1 (en) * 2017-08-09 2019-02-14 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
WO2023092733A1 (en) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variant thereof
WO2024061224A1 (en) * 2022-09-20 2024-03-28 普米斯生物技术(珠海)有限公司 Anti-her2 antibodies and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001743A1 (en) * 1989-08-01 1991-02-21 Cemu Bioteknik Ab Stabilized protein or peptide conjugates
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (en) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69226197T2 (en) * 1991-11-08 1999-02-11 Somatogen Inc HEMOGLOBINE AS A MEDICINE DELIVERY SYSTEM
ES2233928T3 (en) * 1993-10-01 2005-06-16 Teikoku Hormone Mfg. Co., Ltd. DOLASTATIN DERIVATIVES
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
AU2003224916B2 (en) * 2002-04-10 2009-01-08 Genentech, Inc. Anti-HER2 antibody variants
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
BR122018071808B8 (en) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO1991001743A1 (en) * 1989-08-01 1991-02-21 Cemu Bioteknik Ab Stabilized protein or peptide conjugates
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENNIS M S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 277, no. 38, 20 September 2002 (2002-09-20), pages 35035 - 35043, XP002285300, ISSN: 0021-9258 *
FRANCISCO J A ET AL: "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 102, no. 4, 15 August 2003 (2003-08-15), pages 1458 - 1465, XP002280965, ISSN: 0006-4971 *
MAO WEIGUANG ET AL: "EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 781 - 788, XP002343724, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2005294723A1 (en) 2006-04-20
MX2007003907A (en) 2007-05-21
IL182261A0 (en) 2007-07-24
WO2006041641A2 (en) 2006-04-20
RU2007116973A (en) 2008-11-20
BRPI0516577A (en) 2008-09-16
US20060073152A1 (en) 2006-04-06
KR20070073886A (en) 2007-07-10
EP1796718A2 (en) 2007-06-20
JP2008515889A (en) 2008-05-15
US20090123376A1 (en) 2009-05-14
CA2583137A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2005067980A3 (en) Design of therapeutics and therapeutics
WO2006036371A3 (en) Combination therapy
WO2004021968A3 (en) Solution for ungual application
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2005067898A3 (en) Improved sustained release compositions for pulmonary administration of insulin
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2005016286A3 (en) Pyrazine modulators of cannabinoid receptors
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2007146248A3 (en) Stable laquinimod preparations
WO2003074551A3 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2007019865A3 (en) Therapy with cd4 binding peptides and radiation
WO2006085932A3 (en) Anti-viral uses of borinic acid complexes
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
WO2007048027A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2006007671A3 (en) Therapeutically combinations
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
WO2007133944A3 (en) Topical administration of acyclovir
WO2006124753A3 (en) Antipyretic agents against vr1-antagonist-induced increases in body temperature

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 554161

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 182261

Country of ref document: IL

Ref document number: 2005294723

Country of ref document: AU

Ref document number: 2370/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003907

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2583137

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007535700

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005810079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005294723

Country of ref document: AU

Date of ref document: 20050922

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005294723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007/03478

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020077010255

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007116973

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580041758.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005810079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0516577

Country of ref document: BR